VIDEO: New data show Stelara safe, induces long-term remission in UC
Click Here to Manage Email Alerts
In a Healio video exclusive, Jan Wehkamp, MD, global strategy leader for gastroenterology at Janssen Pharmaceuticals, reports key data points from the company’s 3-year, phase 3 UNIFI study.
Among ulcerative colitis patients treated with 90 mg subcutaneous Stelara (ustekinumab, Janssen) every 8 weeks or every 12 weeks in the long-term extension study, 56.3% and 54.1%, respectively, achieved symptomatic remission at week 152, with 98% and 94.6% corticosteroid free; corticosteroid-free symptomatic remission rates were 55.1% and 51.2%, respectively.
Researchers noted no major adverse events.
“We continue to generate new evidence for Stelara, and we hope that through our continued research, we can provide valuable information to help physicians evaluate available treatment options for their patients of all ages living with an untreated or undertreated immune-mediated disease such as ulcerative colitis,” Wehkamp said.
Collapse
Read more about
Click Here to Manage Email Alerts